Fixed|Duration Targeted Therapy with Venetoclax plus ...

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab ...

After 12 cycles of treatment, 85.7% (95% CI, 57.2-98.2) of PV and 90.0% (95% CI, 55.5-99.7) of PVR patients achieved undetectable minimal residual disease (<10- ...

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL

Fixed-duration ibrutinib plus venetoclax achieved deep, durable responses, clinically meaningful PFS, and treatment-free remissions. First-line ...

Fixed-duration Calquence plus venetoclax, with or without ...

Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic ...

Fixed-duration Ibrutinib Plus Venetoclax May Benefit Patients with ...

While the trial results suggested that fixed-duration ibrutinib plus venetoclax may be a beneficial first-line treatment for CLL, the benefit of ...

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL

Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. Patients received 3 cycles of ibrutinib lead-in ...

Fixed-Duration Targeted Therapy with Venetoclax plus ...

Chicago, IL—In the phase 3 CLL14 trial, fixed-duration therapy with the combination of venetoclax (Venclexta) plus obinutuzumab (Gazyva) was superior to the ...

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic ...

Combining ibrutinib and venetoclax has the potential to induce deep responses with time-limited therapy, enabling treatment-free remissions for ...

Venetoclax consolidation after fixed-duration venetoclax ... - PubMed

Background: Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia.

Fixed-Duration Venetoclax plus Obinutuzumab New Standard of ...

“Fixed-duration targeted therapy combining venetoclax and obinutuzumab can be applied safely to elderly CLL patients with comorbidities. Our study showed it ...

Paper: Fixed-Duration Acalabrutinib Plus Venetoclax with or without ...

Background: In patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL), both continuous Bruton tyrosine kinase inhibitor (BTKi) monotherapy and ...

Fixed-Duration Venetoclax Plus Obinutuzumab as First-Line ...

“Fixed-duration targeted therapy combining venetoclax and obinutuzumab can be applied safely in elderly patients with CLL and comorbidities. Our ...

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

The combination of venetoclax plus obinutuzumab or rituximab as first-line therapy has led to a high incidence of undetectable minimal residual ...

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic ...

The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, ...

Venetoclax consolidation after fixed-duration ... - ScienceDirect.com

Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to ...

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS With ...

Fixed-duration venetoclax plus obinutuzumab results in high rates of undetectable MRD at the end of treatment, with over 90% of patients ...

Venetoclax consolidation after fixed-duration ... - The Lancet

Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to ...

Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic ...

These results support first-line treatment with ibrutinib plus venetoclax as an all-oral, once-daily, chemotherapy-free, fixed-duration regimen that provides ...

Long-Term Data Showcase the Clinical Utility of Fixed-Duration ...

Fixed-duration venetoclax plus obinutuzumab demonstrated prolonged remissions compared with chemoimmunotherapy in elderly patients with ...

Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus ...

Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic ...

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment ...

A Phase III trial comparing I+V (15 months [mo]) with chlorambucil-obinutuzumab led to the approval of I+V. However, mathematical disease ...